Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$3.06 USD
-0.01 (-0.33%)
Updated May 3, 2024 04:00 PM ET
After-Market: $3.05 -0.01 (-0.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OVID 3.06 -0.01(-0.33%)
Will OVID be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OVID
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Poseida Therapeutics, Inc. (PSTX) Reports Q4 Loss, Tops Revenue Estimates
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Other News for OVID
Ovid Therapeutics initiated with bullish view at B. Riley, here's why
Ovid Therapeutics initiated with bullish view at H.C. Wainwright, here's why
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Ovid Therapeutics gains on bullish view at Wedbush